Gamithromycin (ML-1709460) Assay Workflow
2026-09-14
Build more physiologically relevant Gamithromycin susceptibility assays by pairing broth microdilution with serum-aware testing and lung-focused PK/PD interpretation. This workflow translates the reference study’s matrix effect into practical choices for respiratory pathogens, caprine mastitis isolates, and translational animal research.
BFH772 (VEGFR2 inhibitor) Workflow Guide
2026-09-14
BFH772 is a selective small-molecule VEGFR2 inhibitor for pathway-focused kinase, cellular, and tumor angiogenesis research. Its water insolubility and limited solution stability make it unsuitable for workflows requiring aqueous formulation or long-term prepared solutions without solvent and vehicle controls.
Cisplatin Beyond DNA Damage: Translational Playbook
2026-09-13
Cisplatin remains a benchmark DNA-damaging compound, but its translational value increasingly depends on understanding resistance biology, ferroptosis, oxidative stress, and assay design. This thought-leadership guide connects CDDP mechanism with practical validation strategies, using recent lung adenocarcinoma research to show how combination hypotheses can be built without overstating preclinical evidence.
Cell Counting Kit-8 Plus in Senescence Research
2026-09-12
Cell Counting Kit-8 Plus provides a rapid, sensitive viability readout for senolytic screening, proliferation studies, and cytotoxicity profiling. This guide shows how to combine its WST-8 chemistry with orthogonal senescence measurements to investigate Tubeimoside I and ATP1A1-related cell death without overinterpreting metabolic signals.
Ruxolitinib Phosphate: JAK/STAT Workflow
2026-09-12
Ruxolitinib phosphate (INCB018424) combines strong JAK1/JAK2 biochemical selectivity with a practical workflow for linking pathway inhibition to apoptosis, mitochondrial remodeling, and pyroptosis. This guide translates recent anaplastic thyroid carcinoma findings into actionable assay design, controls, and troubleshooting strategies for oncology, inflammatory, and autoimmune disease model research.
Gamithromycin: From Ribosome to Lung PK/PD
2026-09-11
A translational analysis of Gamithromycin that connects 50S ribosomal inhibition with lung exposure, serum-adjusted susceptibility, AUC/MIC targets, veterinary applications, and evidence-led study design.
Levofloxacin in Translational Bone Research
2026-09-11
Levofloxacin offers translational researchers a dual-view model: a synthetic fluoroquinolone antibiotic for interrogating bacterial DNA replication and a useful probe for studying osteoblast mineralization and chondrocyte metabolism. This article connects mechanism, assay design, competitive antibiotic strategy, and exposure-aware bone research.
Okadaic acid A4540: PP1 Inhibition Guide
2026-09-10
Okadaic acid (A4540) provides a controlled way to inhibit PP2A preferentially at low nanomolar exposure and PP1 at higher nanomolar exposure, supporting phosphorylation, apoptosis, and signal-transduction workflows. It should be used with concentration-response and vehicle controls, not as a universal phosphatase blocker or as a stand-alone explanation for cell death.
Gamithromycin: Reliable Assay Workflows
2026-09-10
Learn how Gamithromycin (SKU BA1074) can support more interpretable antimicrobial, cell viability, proliferation, and cytotoxicity workflows. This scenario-based guide links formulation, serum effects, protocol controls, and PK/PD interpretation to published evidence and practical laboratory decisions.
RNA Pol II Inhibition and Active Apoptotic Signaling
2026-09-09
Harper et al. show that RNA polymerase II inhibition kills cells through an active apoptotic program rather than through passive depletion of transcripts and proteins. Their identification of the Pol II degradation-dependent apoptotic response, or PDAR, reframes transcription-targeted drug action and provides a mechanistic framework for studying mitochondrial death signaling.
VX-702: p38α MAPK Inhibitor Workflow Guide
2026-09-09
Build more reproducible inflammation, platelet, and kinase-signaling assays with VX-702, an ATP-competitive p38α MAPK inhibitor designed for nanomolar pathway control. This guide connects practical assay setup with emerging evidence that inhibitor-controlled kinase conformation can influence dephosphorylation.
Ferrostatin-1 (Fer-1) for Ferroptosis Assays
2026-09-08
Use Ferrostatin-1 (Fer-1) as a nanomolar rescue control to distinguish ferroptosis from nonspecific oxidative cytotoxicity. This workflow connects mechanistic cell assays with sonodynamic therapy, cancer biology research, and neurodegenerative disease models while emphasizing controls that improve reproducibility.
APEX2 Supports TERT Expression in Human Stem Cells
2026-09-08
A bioRxiv study identifies APEX2, but not its paralog APEX1, as a DNA repair factor required for efficient TERT expression in human embryonic stem cells and melanoma cells. Its RNA-seq and chromatin-immunoprecipitation data connect TERT regulation with repair-prone repetitive DNA, providing a mechanistic framework for studying telomerase control in stem cell biology and cancer.
Protease Inhibitor Cocktail: K1010 Guide
2026-09-07
This scenario-based guide explains how Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO), SKU K1010, helps preserve protein integrity in viability, cytotoxicity, phosphorylation, Western blot, and immunoprecipitation workflows. It covers compatibility, dilution, interpretation, limitations, and practical vendor-selection criteria.
Gamithromycin: Lung-Targeted Research Workflows
2026-09-05
Gamithromycin supports respiratory infection research with a workflow that connects matrix-aware susceptibility testing to lung and phagocytic-cell exposure. This guide translates pharmacokinetic findings into practical assay design, PK/PD interpretation, and troubleshooting for veterinary pathogen studies.